Clinical trial
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
NCT00003508 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003508 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 8 |
| Start date | Mar 8, 1996 |
| Primary completion | Apr 26, 2005 |
| Completion | Apr 26, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 27, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: